drugset / Trial / NCT02203461
Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication
Phase 1
Completed
30 enrolled
Technical University of Munich
Gilead Sciences · collabMUC Research GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Changes in insulin resistance in healthy volunteers with normal body weight (BMI 18-25) after 14 days of STRIBILD®-, Truvada®/Kaletra® or Truvada®/Prezista®/Norvir® intake, measured by hyperinsulinemic euglycemic clamp.
Timeline
- Start
- 2014-07
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobicistat | Small molecule | — | — |
| Subject | Darunavir | Small molecule | 800 mg | — |
| Comparator | Lopinavir | Other / unclassified | 200 mg | — |
| Comparator | Ritonavir | Other / unclassified | 50 mg | — |
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | elvitegravir | Small molecule | — | — |
| Background | Tenofovir disaproxil fumarate | Unknown | — | — |
| Background | emtricitabine | Other / unclassified | — | — |
Indications
No indication recorded.